Oesophago-Gastric Cancer | ATTAX (AG0603G)
A randomised phase II study evaluating a weekly schedule of docetaxel with cisplatin and 5-FU (wTCF) or with capecitabine (wTX) in advanced oesophago-gastric cancer.
Schema
.gif)
Summary
In Australia and New Zealand, there are approximately 3,485 new cases diagnosed and 2,741 deaths annually from oesophageal and gastric cancers. Therapeutic options for patients with advanced oesophageal and gastric cancer include chemotherapy, but current treatments need to be improved upon. This study is assessing the effectiveness of two different combinations of chemotherapy on the growth of tumours and the undesirable side-effects of the treatments. This study will help to decide which treatments are most promising and should be compared with current treatments in the future in an effort to improve the time people live after a diagnosis of oesophageal or gastric cancer.
